Pfizer (PFE) Total Non-Current Liabilities (2009 - 2026)
Pfizer (PFE) reported Total Non-Current Liabilities of $113.5 billion for Q1 2026, up 1.65% year-over-year from $111.7 billion in Q1 2025, and up 1879.23% on a QoQ basis from $5.7 billion in Q4 2025.
Pfizer (PFE) has 18 years of Total Non-Current Liabilities data on file, last reported at $113.5 billion in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 1.65% year-over-year to $113.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.5 billion (up 1.65% YoY) and the FY2025 annual result came in at $5.7 billion, down 7.57% from the prior year.
- Total Non-Current Liabilities rose to $113.5 billion in Q1 2026 per PFE's latest filing, from $5.7 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $121.0 billion in Q3 2024 and bottomed at $5.7 billion in Q4 2025.
- The 5-year median for Total Non-Current Liabilities is $102.0 billion (2025), against an average of $77.6 billion.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities soared 537.15%; it then dropped 15.69% in 2025.
- Tracing PFE's Total Non-Current Liabilities over 5 years: stood at $6.0 billion in 2022, then gained by 0.03% to $6.0 billion in 2023, then gained by 3.45% to $6.2 billion in 2024, then decreased by 7.57% to $5.7 billion in 2025, then jumped by 1879.23% to $113.5 billion in 2026.
- Per Business Quant, the three latest PFE Total Non-Current Liabilities figures stand at $113.5 billion (Q1 2026), $5.7 billion (Q4 2025), and $102.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 100.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 31.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 113.51 Bn |
| Dec 31, 2025 | 5.74 Bn |
| Sep 28, 2025 | 102.03 Bn |
| Jun 29, 2025 | 103.15 Bn |
| Mar 30, 2025 | 111.67 Bn |
| Dec 31, 2024 | 6.21 Bn |
| Sep 29, 2024 | 121.01 Bn |
| Jun 30, 2024 | 112.12 Bn |
| Mar 31, 2024 | 119.93 Bn |
| Dec 31, 2023 | 6.00 Bn |
| Oct 1, 2023 | 109.72 Bn |
| Jul 2, 2023 | 112.82 Bn |
| Apr 2, 2023 | 84.52 Bn |
| Dec 31, 2022 | 6.00 Bn |
| Oct 2, 2022 | 17.22 Bn |
| Jul 3, 2022 | 96.51 Bn |
| Apr 3, 2022 | 90.65 Bn |
| Dec 31, 2021 | 6.54 Bn |
| Oct 3, 2021 | 5.22 Bn |
| Jul 4, 2021 | 91.38 Bn |
| Apr 4, 2021 | 78.19 Bn |
| Dec 31, 2020 | 6.37 Bn |
| Sep 27, 2020 | 5.33 Bn |
| Jun 28, 2020 | 106.56 Bn |
| Mar 29, 2020 | 94.19 Bn |
| Dec 31, 2019 | 5.86 Bn |
| Sep 29, 2019 | 5.54 Bn |
| Jun 30, 2019 | 90.09 Bn |
| Mar 31, 2019 | 81.55 Bn |
| Dec 31, 2018 | 80.93 Bn |
| Sep 30, 2018 | 89.81 Bn |
| Jul 1, 2018 | 79.26 Bn |
| Apr 1, 2018 | 77.47 Bn |
| Dec 31, 2017 | 93.99 Bn |
| Oct 1, 2017 | 106.74 Bn |
| Jul 2, 2017 | 103.42 Bn |
| Apr 2, 2017 | 103.12 Bn |
| Dec 31, 2016 | 105.44 Bn |
| Oct 2, 2016 | 108.77 Bn |
| Jul 3, 2016 | 103.48 Bn |
| Apr 3, 2016 | 94.40 Bn |
| Dec 31, 2015 | 98.39 Bn |
| Sep 27, 2015 | 99.29 Bn |
| Jun 28, 2015 | 89.34 Bn |
| Mar 29, 2015 | 87.41 Bn |
| Dec 31, 2014 | 91.59 Bn |
| Sep 28, 2014 | 89.13 Bn |
| Jun 29, 2014 | 91.42 Bn |
| Mar 30, 2014 | 89.32 Bn |
| Dec 31, 2013 | 91.49 Bn |
| Sep 29, 2013 | 92.65 Bn |
| Jun 30, 2013 | 93.54 Bn |
| Mar 31, 2013 | 99.43 Bn |
| Dec 31, 2012 | 99.27 Bn |
| Sep 30, 2012 | 94.48 Bn |
| Jul 1, 2012 | 97.05 Bn |
| Apr 1, 2012 | 95.02 Bn |
| Dec 31, 2011 | 98.50 Bn |
| Oct 2, 2011 | 98.70 Bn |
| Jul 3, 2011 | 102.00 Bn |
| Apr 3, 2011 | 97.83 Bn |
| Dec 31, 2010 | 100.50 Bn |
| Oct 3, 2010 | 94.77 Bn |
| Jul 4, 2010 | 94.66 Bn |
| Apr 4, 2010 | 96.69 Bn |
| Dec 31, 2009 | 116.89 Bn |
| Sep 27, 2009 | 71.91 Bn |
| Jun 28, 2009 | 73.12 Bn |